Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | TDP2 | O95551 | 3/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847672 | 0.82 | MAOA (0.40) | TDP2PDE3BPDE3AMAPT | |
| SCHEMBL182522 | 0.79 | CASP1 (0.42) | TDP2PARP1MEN1MAPTKMT2A | |
| SCHEMBL542110 | 0.79 | TDP2 (0.49) | AHRCMA1METAP1TDP2PARP1 | |
| SCHEMBL6937 | 0.75 | MAOA (0.48) | AHRTDP2 | |
| SCHEMBL29408741 | 0.75 | MAOA (0.48) | AHRTDP2 | |
| SCHEMBL531586 | 0.75 | TDP2 (0.49) | TDP2SRD5A1MAPT | |
| SCHEMBL8623559 | 0.75 | GAA (0.50) | METAP1TDP2PDE3BPDE3AMAPT | |
| SCHEMBL182798 | 0.73 | TDP2 (0.54) | TDP2PGRPARP1MEN1MAPT | |
| SCHEMBL2919635 | 0.73 | MAOA (0.46) | AHRTDP2MAPT | |
| Hydrochloric Acid SCHEMBL5625931 | 0.73 | MAOA (0.46) | AHRTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796266-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC | 2013-10-03 | — | — | US | disclosed |
| US-8466146-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | WYETH LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8329690-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090281096-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-11-12 | — | — | US | disclosed |
| US-7569564-B2 | Cyclothiocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2009-04-30 | — | — | US | disclosed |
| US-7488822-B2 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1175411-B1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH CORP (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | WYETH LLC | 2003-05-15 | — | — | US | disclosed |
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | WYETH | 2003-03-06 | — | — | US | disclosed |
| US-6509334-B1 | This invention relates to compounds that antagonists of the progesterone receptor, their preparation and utility. Intracellular receptors (IR) form a class of structurally related gene regulators known as \"ligand dependent | AMERICAN HOME PRODUCTS CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-6444668-B1 | IN COMBINATION WITH A PROGESTIN, AN ESTROGEN, OR BOTH; ANTIPROGESTIN IS A 1,4-DIHYDRO-BENZO(D)(1.3)OXAZIN-2-ONE | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-6436929-B1 | 3,1-BENZOXAZINE-2-THIONES; CONTRACEPTION AND THE TREATMENT OF PROGESTERONE-RELATED MALADIES | WYETH | 2002-08-20 | — | — | US | disclosed |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | WYETH | 2002-04-25 | — | — | US | disclosed |
| EP-1173426-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| EP-1173210-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066164-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING ANTIPROGESTINIC AND PROGESTINIC | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045511-A1 | Combination regimens using progesterone receptor modulators | GNRHR, PGR, PRLHR | AHR 145/4885CMA1 1132/4885METAP1 2838/4885 |
| US-20090281096-A1 | CYCLOTHIOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | AHR 750/4885CMA1 2903/4885METAP1 3324/4885 |
| US-20030092711-A1 | Contraceptives; hormone replacement therapy | PGR, GNRHR, GHRHR | AHR 69/4885CMA1 3075/4885METAP1 4116/4885 |
| US-20130072480-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | AHR 750/4885CMA1 2903/4885METAP1 3324/4885 |
| US-20130261112-A1 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators | PGR, PGRMC2, PGRMC1 | AHR 750/4885CMA1 2903/4885METAP1 3324/4885 |
| US-20020049204-A1 | Cyclocarbamate derivatives as progesterone receptor modulators | NR3C1, NR5A1, CNR1 | AHR 357/4885CMA1 1686/4885METAP1 3429/4885 |
| US-20090111802-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | PGR, NR5A1, NR3C1 | AHR 512/4885CMA1 2856/4885METAP1 4493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.